June 29, 2020 / 10:18 AM / 4 days ago

BRIEF-Pharma Mar's Lurbinectedin Receives Acceptance For Clinical Trial Application In China

June 29 (Reuters) - Pharma Mar SA:

* SAYS LURBINECTEDIN RECEIVED ACCEPTANCE FOR ITS CLINICAL TRIAL APPLICATION IN CHINA

* LURBINECTEDIN IS USED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC SMALL CELL LUNG CANCER WITH DISEASE PROGRESSION Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below